Life Sciences Technology / Pharmaceutical Manufacturing Equipment
Strategic Profile
Rising demand for automated, data-driven microbiology QC and regulatory shifts support strong system placements and recurring consumables revenue, while strategic partnerships and operational efficiencies drive expanded commercial reach and margin expansion. The company operates with a recurring revenue model combining hardware systems with proprietary consumables and software solutions.
Cyborg Score Rationale
RPID shows promising growth trajectory with strong consumables growth and improving margins, but operates unprofitably with negative EBITDA. The company has raised capital via debt financing and demonstrates momentum in system placements, but elevated stock volatility and modest market capitalization reflect investor uncertainty.
Top Insights
Full-year 2025 revenue guidance raised to at least $33 million, driven by strong consumable sales (+40%) and operational efficiencies
174 total systems installed with 152 fully validated, including a multi-system order from a top 20 global biopharma customer in Q3 2025
Secured $45 million growth capital from Trinity Capital Inc. via term loan facility
Recurring consumables revenue model provides revenue visibility and improves unit economics over system lifecycle
Named Competitors
Automated Microbial Testing Platforms — Competing automation solutions for pharmaceutical quality control
Recent Developments
(February 2026) Fourth quarter and full year 2025 earnings scheduled for March 12, 2026
(November 2025) Q3 2025 record multi-system customer order from top 20 global biopharma; raised full-year revenue guidance
(2025) Secured $45 million five-year term loan facility with Trinity Capital Inc.
Open the full interactive Rapid Micro Biosystems, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.